The MARGOT/TBCRC052 trial didn't show improvement in pathologic complete response rates with margetuximab for early-stage HER2-positive breast cancer.

MacroGenics argues that margetuximab works by tweaking the “Fc” part of Herceptin – the tail of the ‘Y’ shaped antibody – so that it interacts more efficiently with the immune system ...

Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic HER2-positive breast cancer after at least two previous rounds of therapy. One of the talking points ...